BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 9762351)

  • 1. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
    Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
    Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
    Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
    Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
    Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
    Wang Y; Zhao R; Goldman ID
    Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular, biochemical, and cellular pharmacology of pemetrexed.
    Goldman ID; Zhao R
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
    Tonkinson JL; Marder P; Andis SL; Schultz RM; Gossett LS; Shih C; Mendelsohn LG
    Cancer Chemother Pharmacol; 1997; 39(6):521-31. PubMed ID: 9118464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
    Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):48-54. PubMed ID: 10598555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
    Eismann U; Oberschmidt O; Ehnert M; Fleeth J; Lüdtke FE; Struck S; Schulz L; Blatter J; Lahn MM; Ma D; Niyikiza C; Paoletti P; Hanauske AR
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):567-9. PubMed ID: 16372519
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
    Gangjee A; Vidwans A; Elzein E; McGuire JJ; Queener SF; Kisliuk RL
    J Med Chem; 2001 Jun; 44(12):1993-2003. PubMed ID: 11384244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
    Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
    Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on antifolate drugs targets.
    Costi MP; Ferrari S
    Curr Drug Targets; 2001 Jun; 2(2):135-66. PubMed ID: 11469716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate-based thymidylate synthase inhibitors as anticancer drugs.
    Jackman AL; Calvert AH
    Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.
    Faessel HM; Slocum HK; Jackson RC; Boritzki TJ; Rustum YM; Nair MG; Greco WR
    Cancer Res; 1998 Jul; 58(14):3036-50. PubMed ID: 9679969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
    Schultz RM; Patel VF; Worzalla JF; Shih C
    Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
    Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
    J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.